SCHEMBL279954

SCHEMBL279954

Cc1ccc(C(=O)NS(C)(=O)=O)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.63
HDAC6 Q9UBN7 1/20 0.63
ALDH1A1 P00352 4/20 0.59
GAA P10253 1/20 0.59
SCN9A Q15858 2/20 0.56
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
P4HTM Q9NXG6 2/20 0.53
PTGS2 P35354 2/20 0.53
HPGD P15428 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
LMNA P02545 2/20 0.48
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
PTPN1 P18031 1/20 0.48
POLB P06746 1/20 0.47
HTT P42858 1/20 0.47
NOD2 Q9HC29 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL680561 0.89 MMP13 (0.65) HDAC1HDAC6ALDH1A1GAASCN9A
SCHEMBL29765489 0.82 HDAC1 (0.61) HDAC1HDAC6ALDH1A1GAANPC1
SCHEMBL22097521 0.82 SCN9A (0.54) HDAC1HDAC6SCN9AP4HTMPTPN1
SCHEMBL7987812 0.82 SCN9A (0.55) GAASCN9AP4HTMPTGS2MEN1
SCHEMBL7118965 0.82 ALDH1A1 (0.58) HDAC1HDAC6ALDH1A1SCN9AP4HTM
SCHEMBL3374779 0.82 SCN9A (0.54) ALDH1A1SCN9ANPC1RAB9AP4HTM
SCHEMBL9913954 0.82 KMT2A (0.54) ALDH1A1GAASCN9ANPC1RAB9A
SCHEMBL7990845 0.82 FLT1 (0.65) ALDH1A1SCN9AP4HTMPTGS2LMNA
SCHEMBL1647742 0.82 LMNA (0.54) ALDH1A1SCN9ANPC1RAB9AP4HTM
SCHEMBL364110 0.81 HDAC3 (0.58) HDAC1HDAC6ALDH1A1GAASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9714240-B2 Vinyl autotaxin inhibitor compounds PHARMAKEA, INC. (US) 2017-07-25 US disclosed
WO-2017051355-A1 COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-03-30 WO disclosed
WO-2017017607-A1 BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-02-02 WO disclosed
US-20160222000-A1 VINYL AUTOTAXIN INHIBITOR COMPOUNDS DF 2024 IP ACQUISITION, LLC 2016-08-04 US disclosed
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-1882684-B1 PYRROLIDINE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-12-10 EP disclosed
EP-2593428-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593428-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
WO-2012007868-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed
WO-2011043359-A1 PHARMACEUTICAL PRODUCT CONTAINING AROMATIC HETEROCYCLIC COMPOUND 協和発酵キリン株式会社 (JP) 2011-04-14 WO disclosed
US-7585886-B2 Pyrrolidine derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2009-09-08 US disclosed
US-7585886-B2 Pyrrolidine derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2009-09-08 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090062366-A1 Pyrrolidine derivative or salt thereof ASTELLAS PHARAMA INC. (JP) 2009-03-05 US disclosed
US-20090062366-A1 Pyrrolidine derivative or salt thereof ASTELLAS PHARAMA INC. (JP) 2009-03-05 US disclosed
US-6331628-B1 REACTING A SUBSTITUTED HALOBENZENE WITH POTASSIUM, SODIUM AND/OR ZINC CYANIDE IN THE PRESENCE OF A METALLIC CATALYST NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2001-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062366-A1 Pyrrolidine derivative or salt thereof CASR, CYP2R1, PTH1R HDAC1 1710/4885HDAC6 3294/4885ALDH1A1 2179/4885
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HDAC1 1145/4885HDAC6 2255/4885ALDH1A1 2047/4885
US-20160222000-A1 VINYL AUTOTAXIN INHIBITOR COMPOUNDS ENPP2, SERPINB1, SERPINB10 HDAC1 1392/4885HDAC6 404/4885ALDH1A1 4514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.